Mirum Pharmaceuticals (MIRM) Projected to Announce Earnings on Thursday

Mirum Pharmaceuticals (NASDAQ:MIRM) is projected to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.7279) per share and revenue of $166.0290 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The firm had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same period in the prior year, the firm earned ($0.30) earnings per share. The business’s revenue for the quarter was up 43.3% on a year-over-year basis. On average, analysts expect Mirum Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mirum Pharmaceuticals Stock Down 2.2%

Shares of Mirum Pharmaceuticals stock opened at $114.48 on Thursday. Mirum Pharmaceuticals has a twelve month low of $50.25 and a twelve month high of $130.00. The company has a fifty day moving average price of $108.49 and a 200 day moving average price of $100.00. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. The stock has a market cap of $6.98 billion, a price-to-earnings ratio of -8.41 and a beta of 0.48.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00. Following the completion of the sale, the senior vice president directly owned 3,114 shares of the company’s stock, valued at approximately $373,680. This represents a 46.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 5,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the sale, the chief financial officer owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. The trade was a 10.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 65,315 shares of company stock valued at $6,991,928 in the last three months. Corporate insiders own 8.32% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds have recently made changes to their positions in MIRM. CIBC Private Wealth Group LLC acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth approximately $32,000. Quantbot Technologies LP acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth about $33,000. Quarry LP acquired a new position in shares of Mirum Pharmaceuticals during the third quarter worth approximately $41,000. Comerica Bank boosted its position in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the last quarter. Finally, Osaic Holdings Inc. increased its position in Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares during the period.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wolfe Research initiated coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Royal Bank Of Canada raised their price target on Mirum Pharmaceuticals from $142.00 to $148.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Morgan Stanley boosted their target price on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Thursday, June 11th. Raymond James Financial reiterated a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Finally, CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $143.40.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.